Literature DB >> 11076816

Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension.

A Veyradier1, T Nishikubo, M Humbert, M Wolf, O Sitbon, G Simonneau, J P Girma, D Meyer.   

Abstract

BACKGROUND: The presence of dysfunctional von Willebrand factor (vWF) in pulmonary arterial hypertension (PAH) was suggested to be related to increased proteolysis. METHODS AND
RESULTS: In 10 patients with severe PAH, we studied the proteolysis of plasma vWF (vWF levels, multimeric distribution, proteolytic pattern, and cleaving protease activity) and hemodynamic variables (mean pulmonary artery pressure, cardiac index, and total pulmonary vascular resistance) at baseline and 30 days after initiation of continuous prostacyclin infusion. At baseline, vWF levels were significantly increased, vWF proteolysis was excessive, and vWF-cleaving protease activity remained normal. These biological abnormalities were reversible and paralleled the improvement of hemodynamics under vasodilator treatment with prostacyclin.
CONCLUSIONS: The excessive proteolysis of vWF in PAH is likely to be related to an increased susceptibility of vWF to proteases induced by high shear rates rather than to an enhanced release of enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076816     DOI: 10.1161/01.cir.102.20.2460

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 2.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 3.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 4.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 5.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

6.  Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide.

Authors:  Metin Aytekin; Kulwant S Aulak; Sarah Haserodt; Ritu Chakravarti; Joseph Cody; Omar A Minai; Raed A Dweik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-13       Impact factor: 5.464

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

8.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

Review 9.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

10.  Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.

Authors:  Nadine Al-Naamani; Harold I Palevsky; David J Lederer; Evelyn M Horn; Stephen C Mathai; Kari E Roberts; Russell P Tracy; Paul M Hassoun; Reda E Girgis; Daichi Shimbo; Wendy S Post; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.